Chronic kidney disease, new therapeutic approaches;Maladie rénale chronique, les voies de recherche thérapeutique

Revue du Praticien

Volumn 62, Issue 1, 2012, Pages 72-75

  Boffa, Jean Jacques ^a,b,c   Dussaule, Jean Claude ^a,b,d   Ronco, Pierre ^a,b,c   Chatziantoniou, Christos ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL TENON   (France)

^d HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BARDOXOLONE METHYL; ENDOTHELIN RECEPTOR AGONIST; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; INFLAMMATION; INTERSTITIAL NEPHRITIS; PRIMARY PREVENTION; PROGNOSIS; TREATMENT INDICATION; URINARY EXCRETION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; OLEANOLIC ACID; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTORS, ENDOTHELIN; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84856572823     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charten V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan hypertension investigators. N Engl J Med 1998;338:784-90. (Pubitemid 28135984)
2. Chatziantoniou C, Boffa JJ, Ardaillou R, Dussaule JC. Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin. J Clin Invest 1998;101:2780-9. (Pubitemid 28294587)
3. Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 2001;37:490-6. (Pubitemid 32199017)
4. Gagliardini E, Coma D, Zoja C, et al. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol 2009;297:F1448-5.
5. Wenzel RR, Littke T, Kuranoff S, et al. SPP301. (Avosentan) endothelin antagonist evaluation in diabetic nephropathy study investigators. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009;20:655-64.
6. Mann JF, Green D, Jamerson K, et al. ASCEND study group. Avosentan for overt diabetic nephropathy. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21:527-35.
7. Kohan DE, Pritchett Y, Molitch M, et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011;22:763-72.
8. Border WA, Noble NA, Yamamoto T, et al. Natural inhibitor of transforming growth factor-beta protects against scanring in experimental kidney disease. Nature 1992:360-361-4.
9. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshlma A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003;12:1486-94. (Pubitemid 38056275)
10. Trachtman H, Fervenza FC, Gipson DS, et al. A phase 1, single-dose study of fresolimumab, an anti-TGF- antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011:79;1236-43.
11. Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007;2:906-13.
12. Sharma K, Ix JH, Mathew AV, et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 2011,22:1144-51.
13. Amrouche L, Bonifay R, Anglicheau D. MicroARN et maladies rénales - Un intérêt grandissant. Med Sci (Paris) 2011,27:398-404.
14. Qin W, Chung AC, Huang XR, et al. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol 2011;22:1462-74.
15. Ramant M, Placier S, Rodenas A, et al. Discoidin domain receptor 1 null mice are protected against hypertension-induced renal disease. J Am Soc Nephrol 2006,17:3374-81. (Pubitemid 44865280)
16. Guerrot D, Kerroch M, Placier S, et al. Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy. Am J Pathol 2011;179:83-91.
17. Torres VE, Leof EB. Fibrosis, regeneration, and aging. playing chess with evolution. J Am Soc Nephrol 2011;22:1393-6.
18. Iyoda M, Shibata T, Hirai Y, Kuno Y, Akizawa T. Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease. J Am Soc Nephrol 2011;22:1486-96.
19. Pergola PE, Raskin P, Toto RD, et al. BEAM study investigators. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365:327-36.